BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Employer Resources

  Understanding Your Rights: A Guide to Requesting Disability Accommodations at Work

  When a person notifies their employer that they have a disability, the company must make a good-faith effort to adjust to enable the employee to continue in their job.

  April 19, 2023

   · 

  3 min read

   · 

  Shawna Williams
• 

  Drug Development

  Lilly Seeks First-Line KRAS Treatment with AACR Data Release

  Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

  April 19, 2023

   · 

  4 min read

   · 

  Lisa Munger
• 

  Employer Resources

  Employers Raise the Stakes to Get Employees Back in Office

  As companies prioritize in-person work, many have begun to do more to incentivize a reluctant workforce to come into the office.

  April 19, 2023

   · 

  4 min read

   · 

  Rosemary Scott
• 

  FDA

  AbbVie Wins FDA Approval for New Migraine Indication

  Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.

  April 19, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Data Leak Shows J&J and Legend’s Carvykti Exceeds Expectations

  The leaked data show that Carvykti cuts the risk of disease relapse by 74% versus standard chemotherapy regimens.

  April 19, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Business

  Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results

  Palatin Technologies today announced preliminary fiscal third quarter ended March 31, 2023 Vyleesi® product revenue results.

  April 19, 2023

   · 

  5 min read
• Drug Development

  VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

  VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced new preclinical data showing the positive effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis (“IPF”).

  April 19, 2023

   · 

  9 min read
• Pharm Country

  Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

  Indaptus Therapeutics, Inc. today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.

  April 19, 2023

   · 

  8 min read
• Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

  Enlivex Therapeutics Ltd. today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 16/076,026.

  April 19, 2023

   · 

  3 min read
• Business

  electroCore to Announce First Quarter Financial Results on Wednesday, May 3

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023.

  April 19, 2023

   · 

  1 min read